Healthy volunteer study aims to sharpen future diagnostic tests
NCT ID NCT05160337
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how stable certain biomarkers (like RNA and proteins) are in healthy volunteers. Researchers want to see if things like age, gender, or eating affect these markers. The goal is to make future diagnostic tests more reliable. The study involves 60 healthy adults aged 18 to 85.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Biomarker based IVD tests
- What this could lead to
- If successful, this could help create more reliable diagnostic tests for various diseases by understanding how biomarkers behave in healthy people.
- What could go wrong
- This is a small, early-stage study in healthy volunteers only, so results may not apply to people with diseases. It does not test any treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2025
- Expected to finish
-
Apr 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Participants who sign the informed consent forms for sample collection and data collection both anonymized and reported in CRF. * Able to comply with all study procedures. * Healthy Volunteers having no apparent disease. * Adults, both genders, aged 18-85 years. * Participants with no apparent motor or mental health abnormality. * Participants having no major disabling mental or physical disability that would require hospitalization. * Body weight above 50 kg if male, above 40 kg if female. Exclusion Criteria: * Any subject who did not sign the Informed Consent form. * Any subject who, in the judgment of the Investigator, is likely to be non-compliant during the study, or unable to cooperate because of a language problem or poor mental development. * Any subject in the exclusion period of a previous study according to applicable regulations. * Any subject who cannot be contacted in case of emergency. * Any subject who is the Investigator or any sub-investigator, research assistant, study coordinator, or other staff thereof, directly involved in the conduct of the protocol. * Any subject with a disease that, in the judgement of the investigator, would interfere with the conduct of study or harm the safety of volunteer. * Subjects with disabling disease or abnormal health status are excluded. * Subjects aged below 18 years and older than 85 years are excluded. * Pregnant, parturient and nursing women are excluded. * Subjects deprived of their liberty by a judicial or administrative decision, protected adults and vulnerable persons are excluded. * Subjects who are under legal protection or who are unable to express their consent are not included. * Any subject who reports in the questionnaire of the screening period having one of the following diseases is excluded: * Any psychiatric or neurodegenerative disease or neurologic disorder. * Hypertension. * Any cardiovascular disease. * Any chronic inflammatory disease such as rheumatoid arthritis. * Any cancer. * Frequent headaches and/or migraine, recurrent nausea and/or vomiting. * Any subject who did a blood donation, any volume, within 2 months before inclusion. * Any subject who reports in the questionnaire of the screening period having medication(s) for one or more of the above diseases is excluded. * Drug or alcohol abuse or smoking more than 10 cigarettes or equivalent. * Subjects with no apparent disease and symptoms, but with unknown Covid-19 positivity are not excluded.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Firalis Clinical Investigation Center
RECRUITINGHuningue, 68330, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a protein powder with creatine and fiber boost everyday Well-Being?
- Green tech or hidden stress? bus Drivers' hearts monitored behind the wheel
- Shout it out: can growls and screams raise pain tolerance?
- Scientists probe why brain stimulation works for some and not others
- Tiny doses, big questions: how does the body handle this prodrug?
- First human test of CM583: can this biologic pass the safety check?